Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$5.12
+0.09 (+1.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-365.4M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-35.9%
↓Gross Margin
47.5%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-16.4%
FCF CAGR
—
FCF margin
-15.1%
FCF / Net income
0.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.97B · net income $-1.33B · FCF $-448.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.97B | $2.97B | $3.63B | $3.73B | $5.09B |
| Net Income | $-1.33B | $-1.33B | $-44.0M | $-51.3M | $2.62B |
| EBITDA | $-1.20B | $-1.20B | $85.2M | $134.5M | $3.26B |
| EPS | -1.30 | -1.30 | -0.04 | -0.05 | 2.55 |
| Gross Margin | 47.5% | 47.5% | 50.4% | 49.3% | 59.7% |
| Operating Margin | -11.4% | -11.4% | -1.8% | -2.8% | 4.1% |
| Net Margin | -44.7% | -44.7% | -1.2% | -1.4% | 51.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.04 |
| Current Ratio | 2.32 | 2.32 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-448.3M | $-448.3M | $-365.4M | $-59.5M | $132.8M |
| Returns | |||||
| ROE | -35.9% | -35.9% | -0.8% | -1.0% | 32.4% |
| Valuation | |||||
| P/E | — | — | — | — | 3.32 |
| EV/EBITDA | — | — | 67.48 | 49.69 | 2.38 |
| P/B | 1.42 | 1.42 | 1.26 | 1.40 | 1.07 |
| Growth & Yield | |||||
| Revenue Growth | -18.1% | -18.1% | -2.8% | -26.8% | — |
| EPS Growth | -2932.0% | -2932.0% | 14.2% | -102.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+29.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.04 → -1.30
Residual
+29.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.